Apyx Medical (APYX) Cash & Equivalents (2010 - 2026)

Apyx Medical has reported Cash & Equivalents for 17 years, with the latest figure at $31.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents changed 0.41% year-over-year to $31.1 million; the trailing twelve-month figure through Mar 2026 stood at $31.1 million (changed 0.41% YoY), and the FY2025 full-year result was $31.7 million, changed 0.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $31.1 million, down from $31.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $43.7 million in Q4 2023, with the low at $10.2 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $26.5 million across 5 years, with a median of $28.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 66.98% — and 2023, when it soared 328.3%.
• Apyx Medical's Cash & Equivalents stood at $10.2 million in 2022, then soared by 328.3% to $43.7 million in 2023, then decreased by 27.29% to $31.7 million in 2024, then decreased by 0.0% to $31.7 million in 2025, then decreased by 1.9% to $31.1 million in 2026.
• The last three Cash & Equivalents figures came in at $31.1 million (Q1 2026), $31.7 million (Q4 2025), and $25.1 million (Q3 2025), per Business Quant data.